Characterization of the NADPH-dependent covalent binding of [ 14C]halothane to human liver microsomes: A role for cytochrome P4502E1 at low substrate concentrations

Drug Metabolism and Disposition

Volumn 24, Issue 12, 1996, Pages 1307-1313

  Madan, Ajay ^a   Parkinson, Andrew ^a,b  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

4 METHYLPYRAZOLE; CARBON 14; CYTOCHROME P450; CYTOCHROME P450 INHIBITOR; HALOTHANE; INHALATION ANESTHETIC AGENT; MICROSOME ENZYME; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE;

ARTICLE; BINDING AFFINITY; CATALYSIS; CONCENTRATION RESPONSE; DRUG BINDING; DRUG METABOLISM; ENZYME ACTIVITY; ENZYME SUBSTRATE; HUMAN; HUMAN TISSUE; INHALATION ANESTHESIA; ISOTOPE LABELING; LIVER MICROSOME; PRIORITY JOURNAL; TOXIC HEPATITIS;

AUTORADIOGRAPHY; BIOTRANSFORMATION; CYTOCHROME P-450 CYP2E1; HALOTHANE; HUMANS; KINETICS; MICROSOMES, LIVER; NADP; PROTEIN BINDING;

EID: 0030454131     PISSN: 00909556     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. S. Gelman and R. Van Dykes: Mechanism of halothane-induced hepato-toxicity: another step on a long path. Anesthesiology 68, 479-482 (1988).
2. L. Pohl, J. G. Kenna, H. Satoh, D. Christ, and J. L. Martin: Neoantigens associated with halothane hepatitis. Drug Metab. Rev. 20, 203-217 (1989).
3. D. Vergani, G. Mieli-Vergani, A. Alberti, J. Neuberger, A. L. W. F. Eddleston, M. Davis, and R. Williams: Antibodies to the surface of halothane-altered rabbit hepatocytes in patients with severe halothane-associated hepatitis. N. Engl. J. Med. 303, 66-71 (1980).
4. J. Kenna, J. Neuberger, and R. Williams: Identification by immunoblotting of three halothane-induced liver microsomal polypeptide antigens recognized by antibodies in sera from patients with halothane-associated hepatitis. J. Pharmacol. Exp. Ther. 242, 733-740 (1987).
5. J. Kenna, H. Satoh, D. D. Christ, and L. R. Pohl: Metabolic basis for a drug hypersensitivity: antibodies in sera from patients with halothane hepatitis recognize liver neoantigens that contain the trifluoroacetyl group derived from halothane. J. Pharmacol. Exp. Ther. 245, 1103-1109 (1988).
6. U. Christen, M. Burgin, and J. Gut: Halothane metabolism: immunochemical evidence for molecular mimicry of trifluoroacetylated liver protein adducts by constitutive polypeptides. Mol. Pharmacol. 40, 390-400 (1991).
7. E. Cohen, J. R. Trudell, H. N. Edmunds, and E. Watson: Urinary metabolites of halothane in man. Anesthesiology 43, 392-401 (1975).
8. R. Van Dyke and C. L. Wood: In vitro studies on irreversible binding of halothane metabolites to microsomes. Drug Metab. Dispos. 3, 51-57 (1975).
9. R. Van Dyke and A. J. Gandolfi: Anaerobic release of fluoride from halothane. Relationship to the binding of halothane metabolites to hepatic cellular constituents. Drug Metab. Dispos. 4, 40-44 (1976).
10. J. Sharp, J. R. Trudell, and E. N. Cohen: Volatile metabolites and decomposition products of halothane in man. Anesthesiology 50, 2-8 (1979).
11. G. McLain, I. G. Sipes, and B. R. Brown: An animal model of halothane hepatotoxicity: roles of enzyme induction and hypoxia. Anesthesiology 51, 321-326 (1979).
12. M. Jenner, J. L. Plummer, and M. J. Cousins: Influence of isoniazid, phenobarbital, phenytoin, pregnenolone 16-α-carbonitile, and β-naphthoflavone on halothane metabolism and hepatoloxicity. Drug Metab. Dispos. 18, 819-822 (1990).
13. A. Brown, K. L. Hastings, and A. J. Gandolfi: Generation and detection of neoantigens in guinea pig liver slices incubated with halothane. Int. J. Immunopharmacol. 13, 429-435 (1991).
14. J. Kenna, J. L. Martin, H. Satoh, and L. R. Pohl: Factors affecting the expression of trifluoroacetylated liver microsomal protein neoantigens in rats treated with halothane. Drug Metab. Dispos. 18, 788-793 (1990).
15. L. Gruenke, K. Konopka, D. R. Koop, and L. A. Waskell: Characterization of halothane oxidation by hepatic microsomes and purified cytochromes P-450 using gas chromatographic mass spectrometric assay. J. Pharmacol. Exp. Ther. 246, 454-459 (1988).
16. H. Yin, M. W. Anders, K. R. Korzekwa, L. Higgins, K. E., Thummel, D. Kharasch, and J. P. Jones: Designing safer chemicals: predicting the rates of metabolism of halogenated alkanes. Proc. Natl. Acad. Sci. U.S.A. 92, 11076-11080 (1995).
17. G. Urban, P. Speerschneider, and W. Dekant: Metabolism of the chlorofluorocarbon substitute 1,1-dichloro-2,2,2-trifluoroethane by rat and human liver microsomes: the role of cytochrome P4502E1. Chem. Res. Toxicol. 7, 170-176 (1994).
18. R. Pearce, C. J. McIntyre, A. Madan, U. Sanzgiri, A. Draper, P. L. Bullock, D. C. Cook, L. A. Burton, J. L. Latham, C. J. Nevins, and A. Parkinson: Effects of freezing, thawing and storing human liver microsomes on cytochrome P450 activity. Arch. Biochem. Biophys. 331, 145-169 (1996).
19. Pierce Chemical Company: "BCA Protein Assay Reagent: Technical Bulletin 23225X," pp. 1-16. Pierce Chemical Company, Rockford, IL, 1991.
20. M. Arlotto, D. Greenway, and A. Parkinson: Purification of two isozymes of rat liver microsomal cytochrome P-450 with testosterone 7α-hydroxylase activity. Arch. Biochem. Biophys. 270, 441-457 (1989).
21. R. Peter, R. Böcker, P. H. Beaune, M. Iwasaki, F. P. Guengerich, and C. S. Yang: Hydroxylation of chlorzoxazone as a specific probe for human liver cytochrome P-450IIE1. Chem. Res. Toxicol. 3, 566-573 (1990).
22. 5 on the stoichiometry of P450 2E1-catalyzed reactions. Arch. Biochem. Biophys. 317, 504-513 (1995).
23. 5. Arch. Biochem. Biophys. 248, 158-165 (1986).
24. E. Kharasch, D. Hankins, D. Mautz, and K. E. Thummel: Identification of the enzyme responsible for oxidative halothane metabolism: implications for prevention of halothane hepatitis. Lancet 347, 1367-1371 (1996).
25. S. Surbrook and M. J. Olson: Dominant role of cytochrome P-450 2E1 in human hepatic microsomal oxidation of the CFC-substitute 1,1,1,2-tetrafluoroethane. Drug Metab. Dispos. 20, 518-524 (1992).
26. J. Herbst, U. Koster, R. Kerssebaum, and W. Dekant: Role of P4502E1 in the metabolism of 1,1,2,2-tetrafluoro-1-(2,2,2-trifluoroethoxy)-ethane. Xenobiotica 24, 507-516 (1994).
27. K. Thummel, E. D. Kharasch, T. Podoll, and K. Kunze: Human liver microsomal enflurane defluorination catalyzed by cytochrome P-450 2E1. Drug Metab. Dispos. 21, 350-357 (1993).
28. E. Kharasch and K. E. Thummel: Identification of cytochrome P450 2E1 as the predominant enzyme catalyzing human liver microsomal defluorination of sevoflurane, isoflurane and methoxyflurane. Anesthesiology 79, 795-807 (1993).